Karen Facey | Chair HTAi Rare Disease Interest Group
University of Edinburgh

Day 1 @ 16:10

Panel: Patient Centred Real-World Evidence for Rare Disease Decision-Making

Day 2 @ 09:00

Keynote panel: Redefining clinical value: Navigating the scientific and strategic era of EU Joint Clinical Assessments and Joint Scientific Consultations

-       How can joint clinical assessments reshape patient access across Europe?

-       How can joint scientific consultations influence global evidence strategies?

-       Strategic implications of EUHTA for global clinical development

-       Lessons for orphan medical products (OMPs), practical implications and decision-maker learnings

Moderator: Karen Facey, Chair HTAi Rare Disease Interest Group, University of Edinburgh

Niklas Hedberg, Head Of Pharmacy, Tandvards och Lakemedelsformansverket

Anne Willemsen, Co-chair JCA Subgroup, Zorginstituut Nederland

Jonathan Neal, Head of Central, South and Eastern Europe Takeda and EFPIA European Markets Committee, Takeda

Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

×

Alexander Natz / Keynote panel: Redefining clinical value: Navigating the scientific and strategic era of EU Joint Clinical Assessments and Joint Scientific Consultations

Alexander Natz, Secretary General,
EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law...

CloseMore